Search for a funded project
Explorez notre base de projets financés
Genome-wide CRISPR screens for drug target identification and inhibition of SARS-CoV-2 replication – CRISPR-TARGET-CoV
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the current coronavirus disease 2019 (COVID-19) pandemic. This virus emerged in China at the end of 2019 and has, since then, dramatically spread across the world. As of today (18th of June 2020), SARS-CoV-2 has
Identifying SARS-CoV-2-like and other coronaviruses able to infect humans in bats from Indochina peninsula – BAT-CoV-ASIA
The objective of the project is to identify bat coronaviruses close to SARS-CoV-2 and other alpha and betacoronaviruses in Southeast Asia capable of infecting humans, using metagenomic, phylogeny, structural and cellular biology approaches
Emergence dynamics of Sarbecovirus coronaviruses : Zoonose mecanisms. – EmerCoV
The 21st century began with a wave of emerging epidemic infectious diseases, of which COVID-19 is considered one of the most serious, with a devastating impact worldwide. Seventeen years after the emergence of SARS-CoV from 2002-2003, in 2019, it is again a Betacoronavirus Sarbecovirus (SARS-CoV2, t
Autoantibodies against type I IFNs in Lebanese patients hospitalized with COVID-19. – AAILC
Since 2003, three coronaviruses, SARS, MERS, and SARS-CoV-2, have led to devastating pandemics. Although vaccines are available, new variants and even new coronaviruses could emerge at any time. Understanding the molecular and cellular basis of human protective immunity against SARS-CoV-2 is critica
Identification of SARS-CoV-2 RNA ibinding proteins durig viral replication – CoV-2RBP
The beginning of 2020 has seen the emergence of COVID-19 pandemic, a respiratory disease caused by a novel coronavirus (CoV), the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In the absence of efficient cure or vaccine currently available, there is an imminent need to better underst
Engineering nanobinders to block SARS-CoV-2 entry – SARS2BlockEntry
The novel coronavirus SARS-CoV-2 has recently emerged as a human pathogen in China’s Hubei province, causing severe respiratory illness and pneumonia. According to the World Health Organization (WHO) on March 17th, 2020, there have been over 180,000 cases globally, leading to at least 7,500 deaths.
NSP3 polyprotein of SARS-CoV2: structural studies and its exploration in drug screening campaign – COVNSP3
Severe Acute Respiratory syndrome (SARS) is an alarming emerging infectious disease caused by coronavirus (CoV). The current COVID-19 pandemic, which originated in the Wuhan region of China, is caused by a novel coronavirus, SARS-CoV2 which is more infectious than the 2003 SARS-CoV and which has led
LabCom PHYTOMAR’INNOV – PHYTOMAR
The PHYTOMAR'INNOV Joint Laboratory aims at the sustainable creation of a laboratory of excellence for the eco-design of innovative active ingredients, composed of molecules derived from marine algal and plant resources, allowing the design of products for the prevention of infectious diseases, in p
Identification of novel inhibitors against emerging human coronaviruses SARS-CoV and MERS-CoV from host cellular transcriptionic signatures – CoV-SigN
In 2012, a novel human coronavirus (MERS-CoV) was identified in the Middle East as the causative agent of a severe acute and/or fatal respiratory syndrome. Since its identification, it has been responsible for 211 laboratory-confirmed cases including 88 deaths. Most cases are sporadic but human-to-h
Inhibition of coronaviruses infections using innovative nanostructures – NanoMERS
The main objectives are 1. Identification of most promising anti-MERS-CoV nanostructures using in vitro tests 2. Determination of the pharmacokinetic of the best nanostructures 3. Pulmonary delivery using nebulization of mice 4. Testing of most promising anti-MERS structures in MERS-CoV infecte